PH30757A - Insulin formulation. - Google Patents

Insulin formulation.

Info

Publication number: PH30757A
Authority: PH; Philippines
Prior art keywords: insulin; formulation; zinc; total; present
Prior art date: 1993-08-13

Application number

PH48764A

Other languages

English (en)

Inventor

Hoffmann James Arthur

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-13

Filing date

1994-08-09

Publication date

1997-10-17

1994-08-09 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1997-10-17 Publication of PH30757A publication Critical patent/PH30757A/en

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 12
238000009472 formulation Methods 0.000 title abstract 7
239000000203 mixture Substances 0.000 title abstract 7
102000004877 Insulin Human genes 0.000 title abstract 6
108090001061 Insulin Proteins 0.000 title abstract 6
229940125396 insulin Drugs 0.000 title abstract 6
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 2
239000011701 zinc Substances 0.000 abstract 2
229910052725 zinc Inorganic materials 0.000 abstract 2
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
102000007327 Protamines Human genes 0.000 abstract 1
108010007568 Protamines Proteins 0.000 abstract 1
239000013078 crystal Substances 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
230000005923 long-lasting effect Effects 0.000 abstract 1
229940048914 protamine Drugs 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Hematology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PH48764A 1993-08-13 1994-08-09 Insulin formulation. PH30757A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/106,106 US5534488A (en)	1993-08-13	1993-08-13	Insulin formulation

Publications (1)

Publication Number	Publication Date
PH30757A true PH30757A (en)	1997-10-17

Family

ID=22309529

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH48764A PH30757A (en)	1993-08-13	1994-08-09	Insulin formulation.

Country Status (27)

Country	Link
US (1)	US5534488A (de)
EP (1)	EP0646379B1 (de)
JP (1)	JPH07149660A (de)
KR (1)	KR950005324A (de)
CN (1)	CN1109364A (de)
AT (1)	ATE207761T1 (de)
AU (1)	AU674975B2 (de)
BR (1)	BR9403204A (de)
CA (1)	CA2129763A1 (de)
CO (1)	CO4230235A1 (de)
CZ (1)	CZ193794A3 (de)
DE (1)	DE69428860T2 (de)
DK (1)	DK0646379T3 (de)
ES (1)	ES2164691T3 (de)
HU (1)	HUT67853A (de)
IL (1)	IL110581A0 (de)
NO (1)	NO942959L (de)
NZ (1)	NZ264197A (de)
PE (1)	PE14495A1 (de)
PH (1)	PH30757A (de)
PL (1)	PL177002B1 (de)
PT (1)	PT646379E (de)
RU (1)	RU2135205C1 (de)
TW (1)	TW326394B (de)
UA (1)	UA27874C2 (de)
YU (1)	YU50494A (de)
ZA (1)	ZA945939B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5578238A (en) *	1992-10-30	1996-11-26	Lord Corporation	Magnetorheological materials utilizing surface-modified particles
YU18596A (sh) *	1995-03-31	1998-07-10	Eli Lilly And Company	Analogne formulacije monomernog insulina
CO4970787A1 (es) *	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1396272A1 (de) *	1997-12-23	2004-03-10	Eli Lilly & Company	Unlöslische Insulin Zusammensetzungen zur Regelung der Blutglukose
US6956021B1 (en) *	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
WO2001000675A1 (en) *	1999-06-29	2001-01-04	Eli Lilly And Company	Protamine-free insoluble acylated insulin compositions
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
JP2003528149A (ja) *	2000-03-24	2003-09-24	ジェネンテック・インコーポレーテッド	軟骨性疾患の治療のためのインスリンの使用
EP1247283B1 (de) *	2000-10-06	2006-08-16	The Adviser - Defence Research & Development Organisation	Magnetosensitive flüssigkeit zusammenstellung und herstellungsverfahren
EP1344229B1 (de) *	2000-11-29	2008-03-05	The Adviser Defence Research & Development Organisation, Ministry of Defence, Government of India	Magnetorheologische fluidzusammensetzung und prozess zu ihrer herstellung
EP1772464B1 (de) *	2001-02-09	2009-08-12	Genentech, Inc.	Verfahren zur Identifizierung von indirekten IGF-1-Agonisten
DE10114178A1 (de) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ES2664189T3 (es)	2002-01-09	2018-04-18	Emisphere Technologies, Inc.	Polimorfos de 4-(4-cloro-2-hidroxibenzoil)aminobutanoato de sodio
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
RU2251426C1 (ru) *	2003-09-18	2005-05-10	Цыганков Владимир Владимирович	Способ получения инсулина из природного источника и инсулин
EP1711220A1 (de) *	2004-01-16	2006-10-18	Biodel, Inc.	Sublinguale arzneimittelabgabevorrichtung
US20080085298A1 (en) *	2004-03-12	2008-04-10	Biodel, Inc.	Rapid Mucosal Gel or Film Insulin Compositions
CA2558835C (en) *	2004-03-12	2011-06-28	Biodel, Inc.	Rapid acting drug delivery compositions
US20080090753A1 (en) *	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) *	2004-03-12	2008-04-24	Biodel, Inc.	Rapid mucosal gel or film insulin compositions
ES2729825T3 (es)	2004-05-06	2019-11-06	Emisphere Tech Inc	Formas poliméricas cristalinas de N-[8-(2-hidroxibenzoil)amino]caprilato monosódico
WO2005117854A2 (en) *	2004-05-14	2005-12-15	Emisphere Technologies, Inc.	Aryl ketone compounds and compositions for delivering active agents
CA2910494C (en)	2004-07-19	2018-10-23	Biocon Limited	Insulin-oligomer conjugates, formulations and uses thereof
CA2573856A1 (en) *	2004-08-03	2006-02-16	Emisphere Technologies, Inc.	Antidiabetic oral insulin-biguanide combination
US20060078623A1 (en) *	2004-08-13	2006-04-13	Emisphere Technologies, Inc.	Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
RU2288000C1 (ru) *	2005-04-27	2006-11-27	Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН)	Раствор инсулина для перорального введения
US8084420B2 (en) *	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US7713929B2 (en) *	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US7718609B2 (en) *	2006-04-12	2010-05-18	Biodel Inc.	Rapid acting and long acting insulin combination formulations
ES2579229T3 (es)	2007-03-13	2016-08-08	Jds Therapeutics, Llc	Procedimientos y composiciones para la liberación sostenida de cromo
WO2008124522A2 (en) *	2007-04-04	2008-10-16	Biodel, Inc.	Amylin formulations
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
RU2453332C2 (ru)	2007-10-16	2012-06-20	Байокон Лимитид	Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
US20090175840A1 (en) *	2008-01-04	2009-07-09	Biodel, Inc.	Insulin formulations for insulin release as a function of tissue glucose levels
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
SG10201403840VA (en)	2009-07-06	2014-10-30	Sanofi Aventis Deutschland	Aqueous insulin preparations containing methionine
PL2498801T3 (pl)	2009-11-13	2018-08-31	Sanofi Aventis Deutschland	Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
SI2498802T1 (sl)	2009-11-13	2015-05-29	Sanofi-Aventis Deutschland Gmbh	Farmacevtski sestavek, ki vsebuje agonist GLP-1, inzulin in metionin
US20130085101A1 (en) *	2010-02-22	2013-04-04	Case Western Reserve University	Long-acting insulin analogue preparations in soluble and crystalline forms
BR112013004756B1 (pt)	2010-08-30	2020-04-28	Sanofi Aventis Deutschland	uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
JP6152346B2 (ja)	2011-03-01	2017-06-21	ジェーディーエスセラピューティックス、エルエルシーＪＤＳＴｈｅｒａｐｅｕｔｉｃｓ，ＬＬＣ	糖尿病、低血糖、および関連障害の治療および予防のためのインスリンとクロムの組成物
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US11865121B2 (en)	2016-02-11	2024-01-09	Nutrition21, LLC	Chromium containing compositions for improving health and fitness

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2626228A (en) *	1945-05-17	1953-01-20	Novo Terapeutisk Labor As	Method of producing crystalline insulin
US2882202A (en) *	1950-04-05	1959-04-14	Novo Terapeutisk Labor As	Insulin crystal preparations and methods of producing them
US2882203A (en) *	1951-06-26	1959-04-14	Novo Terapeutisk Labor As	Injectable insulin preparation with protracted effect
US2849370A (en) *	1953-06-04	1958-08-26	Novo Terapeutisk Labortorium A	Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) *	1953-08-19	1963-08-27	Christensen Henry Marinus	Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) *	1953-11-13	1958-01-14	Novo Terapeutisk Labor As	Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) *	1953-11-14	1957-07-16	Novo Terapeutisk Labor As	Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) *	1957-07-18	1962-10-23	Nordisk Insulinlab	Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) *	1979-08-22	1981-03-12	Hoechst Ag, 6000 Frankfurt	Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3101382A1 (de) *	1981-01-17	1982-09-02	Hoechst Ag, 6000 Frankfurt	"verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
FI78616C (fi) *	1982-02-05	1989-09-11	Novo Industri As	Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
SU1131507A1 (ru) *	1982-05-28	1984-12-30	Черновицкий Ордена Трудового Красного Знамени Государственный Университет	Способ получени инсулина
DE3511269A1 (de) *	1985-04-12	1986-10-09	Veb Berlin-Chemie, Ddr 1199 Berlin	Verfahren zur reinigung von insulin
PH23446A (en) *	1986-10-20	1989-08-07	Novo Industri As	Peptide preparations
DE3827533A1 (de) *	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus

1993
- 1993-08-13 US US08/106,106 patent/US5534488A/en not_active Expired - Fee Related
1994
- 1994-08-04 HU HU9402287A patent/HUT67853A/hu unknown
- 1994-08-08 IL IL11058194A patent/IL110581A0/xx not_active IP Right Cessation
- 1994-08-08 BR BR9403204A patent/BR9403204A/pt not_active Application Discontinuation
- 1994-08-08 ZA ZA945939A patent/ZA945939B/xx unknown
- 1994-08-08 PE PE1994248043A patent/PE14495A1/es not_active Application Discontinuation
- 1994-08-08 NZ NZ264197A patent/NZ264197A/en unknown
- 1994-08-09 PL PL94304600A patent/PL177002B1/pl unknown
- 1994-08-09 DK DK94305883T patent/DK0646379T3/da active
- 1994-08-09 CA CA002129763A patent/CA2129763A1/en not_active Abandoned
- 1994-08-09 RU RU94028671A patent/RU2135205C1/ru active
- 1994-08-09 AT AT94305883T patent/ATE207761T1/de not_active IP Right Cessation
- 1994-08-09 KR KR1019940019550A patent/KR950005324A/ko not_active Abandoned
- 1994-08-09 UA UA94085696A patent/UA27874C2/uk unknown
- 1994-08-09 TW TW083107259A patent/TW326394B/zh active
- 1994-08-09 ES ES94305883T patent/ES2164691T3/es not_active Expired - Lifetime
- 1994-08-09 PT PT94305883T patent/PT646379E/pt unknown
- 1994-08-09 CO CO94035010A patent/CO4230235A1/es unknown
- 1994-08-09 NO NO942959A patent/NO942959L/no not_active Application Discontinuation
- 1994-08-09 EP EP94305883A patent/EP0646379B1/de not_active Expired - Lifetime
- 1994-08-09 DE DE69428860T patent/DE69428860T2/de not_active Expired - Fee Related
- 1994-08-09 PH PH48764A patent/PH30757A/en unknown
- 1994-08-10 JP JP6188204A patent/JPH07149660A/ja not_active Withdrawn
- 1994-08-10 CN CN94109082A patent/CN1109364A/zh active Pending
- 1994-08-10 CZ CZ941937A patent/CZ193794A3/cs unknown
- 1994-08-10 YU YU50494A patent/YU50494A/sh unknown
- 1994-08-12 AU AU70247/94A patent/AU674975B2/en not_active Ceased

Also Published As

Publication number	Publication date
KR950005324A (ko)	1995-03-20
ZA945939B (en)	1996-02-08
PL304600A1 (en)	1995-02-20
RU2135205C1 (ru)	1999-08-27
YU50494A (sh)	1997-01-08
JPH07149660A (ja)	1995-06-13
TW326394B (en)	1998-02-11
PE14495A1 (es)	1995-06-02
US5534488A (en)	1996-07-09
AU7024794A (en)	1995-02-23
CO4230235A1 (es)	1995-10-19
NZ264197A (en)	1997-01-29
DE69428860T2 (de)	2002-05-02
ES2164691T3 (es)	2002-03-01
HU9402287D0 (en)	1994-09-28
CN1109364A (zh)	1995-10-04
UA27874C2 (uk)	2000-10-16
DK0646379T3 (da)	2001-12-03
CZ193794A3 (en)	1995-03-15
PL177002B1 (pl)	1999-09-30
HUT67853A (en)	1995-05-29
NO942959D0 (no)	1994-08-09
AU674975B2 (en)	1997-01-16
DE69428860D1 (de)	2001-12-06
ATE207761T1 (de)	2001-11-15
BR9403204A (pt)	1995-04-18
PT646379E (pt)	2002-03-28
IL110581A0 (en)	1994-11-11
EP0646379A1 (de)	1995-04-05
NO942959L (no)	1995-02-14
EP0646379B1 (de)	2001-10-31
CA2129763A1 (en)	1995-02-14

Publication	Publication Date	Title
IL110581A0 (en)	1994-11-11	Insulin formulation
AU610636B2 (en)	1991-05-23	Stabilised human protein preparations
IL72494A (en)	1988-02-29	Homologues of aprotinin with other aminoacids in position 15,instead of lysine,their preparation and pharmaceutical compositions containing them
WO1995013297A3 (en)	1995-06-15	Improved immunogenic compositions against human gastrin 17
WO1994001006A3 (en)	1994-03-31	Composition for use as a food or food supplement
CA2015186A1 (en)	1990-10-24	Nutrient composition
AU8188087A (en)	1988-06-02	Variants of hirudin, their use and their preparation
AU2670495A (en)	1995-12-05	Ifn-beta liquid formulations
AU4905990A (en)	1990-08-09	Hot-melt polyurethane compositions and their usea in bonding shoes
AU624079B2 (en)	1992-06-04	Novel fluorinated derivatives of amino acids usable more particularly as surfactants or cosurfactants and preparations for biomedical use incorporating these derivatives
AU8375891A (en)	1992-03-19	Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
HU9402648D0 (en)	1994-11-28	3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens
CA2168570A1 (en)	1995-03-30	Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid
EP0300741A3 (de)	1990-05-16	Humanes Thymopoietin
CA2153071A1 (en)	1994-07-21	Derivatized calcitonins
EP0292302A3 (de)	1990-04-25	Menschliches Splenin
CA2247998A1 (en)	1997-09-04	Fragments of cr1 and their use
HU201445B (en)	1990-11-28	Herbicide composition containing sulfonyl-urea derivative as active component and glycinamide derivative as antidotum
AU6985287A (en)	1987-09-17	1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3- {(substituted amino)carbonyl}-2-thioxo(or oxo)-5-pyrimidine -carboxylic acids and esters